Mirum Pharmaceuticals: recent performance snapshot

Mirum Pharmaceuticals (MIRM) has attracted attention after a strong year to date, with the stock up about 31% and a total return of roughly 127% over the past year.

After this strong run, the share price has recently cooled, with the latest close at $102.19, a 1 day share price return of down 8.3% and a 7 day share price return of down 4.6%. The 1 year total shareholder return remains very large and the 5 year total shareholder return sits near 5x.

If rare disease exposure has your attention, it can be useful to see what else is moving in healthcare by scanning 32 healthcare AI stocks

With Mirum Pharmaceuticals now valued at about US$6.8b and trading at a discount to some analyst targets and intrinsic estimates, you have to ask: is this a rare disease stock on sale, or is the market already pricing in future growth?

Most Popular Narrative: 21.2% Undervalued

At a last close of $102.19 versus a most followed fair value estimate of about $129.73, the current Mirum Pharmaceuticals price sits well below that narrative target, which is built on detailed assumptions about future revenue growth, profitability and cash flows discounted at 7.24%.

Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.

Curious what kind of revenue curve and margin profile would need to play out for this valuation to hold up? The narrative leans on sustained double digit top line expansion, a clear path from current losses into positive earnings, and a forward profit multiple more often associated with faster growing sectors. Want to see how those moving parts fit together and what the market would be asked to pay for those future earnings?

Result: Fair Value of $129.73 (UNDERVALUED)

However, this narrative can quickly shift if key registrational trials disappoint, or if pressure on rare disease pricing limits Livmarli and bile acid portfolio revenue potential.

Another way to look at the valuation

The earlier fair value view leans heavily on detailed cash flow and earnings forecasts. A simpler check uses the current P/S of 10.9x compared with the US Biotechs industry at 10.9x, peers at 11.5x and a fair ratio of 9.3x, which points to a richer price tag and less margin for error if growth or pricing assumptions soften.

Next Steps

Seeing both strong returns and valuation debate in the article, it makes sense to check the underlying data, weigh the upside and the risks, and then decide how comfortable you are with the current setup by reviewing the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop with a single stock story. Broaden your watchlist with focused stock ideas sourced from screeners that highlight quality, value and resilience.

• Target potential mispricings by scanning 50 high quality undervalued stocks that combine solid fundamentals with prices that do not fully reflect their financial profile.
• Strengthen your income stream by reviewing 12 dividend fortresses that pair higher yields with an emphasis on staying power.
• Reduce portfolio surprises by checking 66 resilient stocks with low risk scores built around companies with more resilient financial and risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.